Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled
3 hours ago
- #GIP infusion
- #semaglutide
- #type 2 diabetes
- 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide did not improve glycaemic control in people with type 2 diabetes.
- The study was a randomized, double-blind, placebo-controlled trial with four groups: placebo+placebo, placebo+GIP, semaglutide+placebo, and semaglutide+GIP.
- Primary outcome was change in 14-day mean glucose from baseline to 14 weeks; GIP showed no significant effect vs placebo alone or as add-on to semaglutide.
- Adverse events included injection site reactions (36% of participants) and more frequent gastrointestinal events with semaglutide treatment.
- Limitations include a high dropout rate (16%), preventing firm conclusions on GIP effects as add-on to placebo.